HAHirofumi Akita

Hirofumi Akita

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hirofumi Akita has a total of 315 co-authors. Here are the top co-authors by number of shared publications:

  • Shinichiro Hasegawa

    Department of Gastroenterological Surgery, Graduate School of Medicine, The University of Osaka, Suita, Japan

    21 shared publications
  • Yuichiro Doki

    Department of Gastroenterological Surgery, Graduate School of Medicine, The University of Osaka, Suita, Japan

    18 shared publications
  • Yosuke Mukai

    Department of Gastroenterological Surgery, Graduate School of Medicine, The University of Osaka, Suita, Japan

    17 shared publications
  • Hidenori Takahashi

    Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, 2-15 Yamadaoka, Suita, Osaka, 565-0871, Japan

    16 shared publications
  • Hidetoshi Eguchi

    Department of Gastroenterological Surgery, Graduate School of Medicine, The University of Osaka, Suita, Japan

    14 shared publications
  • Takehiro Noda

    Department of Gastroenterological Surgery, Graduate School of Medicine, The University of Osaka, Suita, Japan

    14 shared publications

Latest Publications

  • Open Access

    Self-assembling peptide hydrogel SPG-178 effectively prevents postoperative pancreatic fistula compared with polyglycolic acid mesh with fibrin glue in rats

    by Takeshi Kado, Yoshito Tomimaru, Hirofumi Akita, Koji Uesugi, Kosuke Tahara, Hiroki Ueda, Yoshihiro Sakano, Kunihito Gotoh, Yosuke Mukai, Kazuki Sasaki, et al.

  • Early Recurrence Limits Post-recurrence Therapy in Biliary Tract Cancer: A Rationale for Neoadjuvant Chemotherapy

    by Daisaku Yamada, Hirofumi Akita, Yosuke Mukai, Kazuki Sasaki, Shinichiro Hasegawa, Yoshito Tomimaru, Takehiro Noda, Tadafumi Asaoka, Junzo Shimizu, Hidenori Takahashi, et al.

  • Open Access

    Enoxaparin attenuates early postoperative elevation of D-dimer following hepatobiliary and pancreatic surgery

    by Shu Aoyama, Takehiro Noda, Hirofumi Akita, Go Shinke, Yoshifumi Iwagami, Yutaka Takeda, Hiroshi Wada, Akira Tomokuni, Junzo Shimizu, Tadafumi Asaoka, et al.

    Purpose: We previously reported the safety and efficacy of postoperative enoxaparin administration for venous thromboembolism prophylaxis after hepatobiliary and pancreatic (HBP) surgery in the multicenter, randomized, controlled phase II CSGO-HBP-013 trial. Here, we report a post hoc analysis investigating the effect of postoperative enoxaparin administration on changes in coagulation markers after HBP surgery. Methods: We analyzed data from the CSGO-HBP-013 trial. Patients were allocated in a 1:1 ratio to the control or enoxaparin group, and analyses were performed in the as-treated population. Platelet count, prothrombin time, activated partial thromboplastin time, and D-dimer levels were evaluated preoperatively and on postoperative days (POD) 1, 3, 5, and 7. Results: We analyzed 127 patients in the control group and 117 in the enoxaparin group. Postoperative platelet count, prothrombin time, and activated partial thromboplastin time did not differ significantly between the two groups at any time point after surgery. In contrast, the postoperative elevation of D-dimer was attenuated in the enoxaparin group, with a significant difference on POD 3 (5.54 vs. 4.31 µg/mL, p = 0.027) and a trend toward lower levels on POD 5 (11.6 vs. 7.95 µg/mL, p = 0.067). In subgroup analyses, this attenuation was most pronounced in patients who underwent anatomical hepatectomy ( n = 84, POD 3: 7.71 vs. 4.93 µg/mL, p = 0.038). Conclusion: Postoperative enoxaparin administration attenuates early D-dimer elevation after HBP surgery. This effect was particularly evident in anatomical hepatectomy, suggesting that enoxaparin might have a preferential attenuating effect on postoperative hypercoagulability in this subgroup.

  • ASO Author Reflections: Early Recurrence Limits Post-Recurrence Therapy in Biliary Tract Cancer: A Rationale for Neoadjuvant Chemotherapy

    by Daisaku Yamada, Hirofumi Akita, Yosuke Mukai, Kazuki Sasaki, Shinichiro Hasegawa, Yoshito Tomimaru, Takehiro Noda, Tadafumi Asaoka, Junzo Shimizu, Hidenori Takahashi, et al.

  • ASO Visual Abstract: Early Recurrence Limits Post-Recurrence Therapy in Biliary Tract Cancer: A Rationale for Neoadjuvant Chemotherapy

    by Daisaku Yamada, Hirofumi Akita, Yosuke Mukai, Kazuki Sasaki, Shinichiro Hasegawa, Yoshito Tomimaru, Takehiro Noda, Tadafumi Asaoka, Junzo Shimizu, Hidenori Takahashi, et al.

  • A soft tissue mass around the arteries after pancreatectomy: the association with local recurrence and the impact of neoadjuvant radiotherapy in pancreatic ductal adenocarcinoma

    by Keisuke Toya, Yoshito Tomimaru, Hirofumi Akita, Yosuke Mukai, Kazuki Sasaki, Shinichiro Hasegawa, Daisaku Yamada, Takehiro Noda, Shogo Kobayashi, Atsushi Nakamoto, et al.

    The presence of a soft tissue mass (STM) around the arteries is often observed after pancreatectomy. Although a STM frequently represents local recurrence, it can also reflect benign postoperative changes. However, the frequency of STMs and the factors determining whether its presence leads to local recurrence or remains benign have not been studied. This study aimed to determine the frequency of STM after pancreatectomy and to identify the clinical factors associated with the development of local recurrence. A total of 246 patients who underwent pancreatectomy at a single institution were analyzed retrospectively. The presence of a STM was assessed by follow-up computed tomography, and its association with local recurrence was evaluated. Among the 246 patients, 33 (13.4%) developed STM after pancreatectomy, and all cases occurred in patients with pancreatic ductal adenocarcinoma (PDAC). Among the 133 patients who underwent pancreatectomy for PDAC, 33 (24.8%) developed STM, 23 (69.7%) of which progressed to local recurrence. No significant predictive factors for STM occurrence were identified in the PDAC patients. However, among the PDAC patients with STM, those who had received neoadjuvant radiotherapy were significantly less likely to develop local recurrence than those who had not (P = 0.0259). STMs occurred after pancreatectomy only in patients with PDAC, and neoadjuvant radiotherapy may influence whether the STM progresses to local recurrence, although the sample size was limited. No predictive factors associated with the development of STMs in patients with PDAC were identified.

  • Open Access

    Impact of preoperative skeletal muscle mass on the healing time of postoperative pancreatic fistula after pancreaticoduodenectomy

    by Takuro Takeuchi, Yoshito Tomimaru, Hirofumi Akita, Yosuke Mukai, Kazuki Sasaki, Shinichiro Hasegawa, Daisaku Yamada, Takehiro Noda, Yuichiro Doki, Hidetoshi Eguchi

    Background: Postoperative pancreatic fistula (POPF) is a serious complication following pancreaticoduodenectomy (PD). While numerous studies have investigated POPF incidence and risk factors, few have focused on POPF healing time (POPF-HT). Skeletal muscle mass has been increasingly recognized as an endocrine organ involved in interorgan communication. The aim of this study was to evaluate how skeletal muscle mass influenced the healing time of POPF after PD. Methods: This investigation included patients who developed POPF of grade B–C after PD with pancreaticojejunostomy during the study period. POPF-HT was defined as the duration from the date of PD to the removal of all drains placed for POPF treatment. Skeletal muscle mass was assessed based on preoperative computed tomography images. Clinical factors associated with POPF-HT were analyzed, including skeletal muscle index (SMI). Results: The mean POPF-HT was 40 ± 15 days (median: 37 days; range: 21–105 days). Compared to those with high SMI, patients with low SMI had a significantly longer POPF-HT (46 ± 18 days vs. 37 ± 11 days, p = 0.0101). In univariate analysis, low SMI was significantly associated with prolonged POPF-HT (hazard ratio: 0.5655, 95% confidence interval: 0.3687–0.8673, p = 0.0090). Kaplan–Meier curves confirmed that patients with low SMI exhibited significantly delayed cumulative POPF healing ( p = 0.0065). Conclusion: Decreased skeletal muscle mass is significantly associated with prolonged POPF-HT after PD. Therefore, preoperative SMI may serve as a potentially modifiable factor associated with POPF-HT.

  • Open Access

    Relationship Between Radiographic and Pathological Portal Vein‐Superior Mesenteric Vein Involvement in Neoadjuvant Treatment for Pancreatic Cancer: A Comparative Study of Neoadjuvant Chemotherapy and Chemoradiotherapy

    by Naoko Sekiguchi, Hidenori Takahashi, Hirofumi Akita, Kazuki Sasaki, Shinichiro Hasegawa, Yoshifumi Iwagami, Daisaku Yamada, Yoshito Tomimaru, Tadafumi Asaoka, Takehiro Noda, et al.

    Background: The relationship between the radiographic portal vein‐superior mesenteric vein (PV‐SMV) involvement and pathological PV‐SMV (pPV) invasion has been established in upfront surgery cases of pancreatic cancer (PC); however, evidence remains limited for patients receiving neoadjuvant therapy (NAT). This study aimed to evaluate the association of radiographic findings with pPV invasion in patients treated with NAT, and to examine whether this association differs between patients treated with neoadjuvant chemotherapy (NAC) and neoadjuvant chemoradiotherapy (NACRT). Methods: We retrospectively analyzed patients with PC whose tumors contacted the PV‐SMV on radiographic imaging before or after NAT. The relationship between radiographic findings and pPV invasion was evaluated in subgroups defined by pre‐ and post‐NAT imaging findings. Results: Tumor size, PV‐SMV contact length, and contact angle were significantly reduced in post‐NAT imaging. Radiographic PV‐SMV involvement showed limited association with pPV invasion in the entire cohort. The overall pPV invasion rate was 15% and did not differ between the NAC and NACRT groups (17% vs. 13%, p = 0.790). Among patients with a pre‐NAT tumor size of < 20 mm, the pPV invasion rate was significantly lower in the NACRT group than in the NAC group (29% vs. 0%, p = 0.007). This difference was not observed in patients with a pre‐NAT tumor size ≥ 20 mm (12% vs. 19%, p = 0.438). Across other radiographic classifications, pPV invasion rates remained comparable between treatment groups. Conclusions: The association of radiographic findings with pPV invasion differs between patients treated with NAC and NACRT in patients with small tumors.

  • Open Access

    Current status and short-term results regarding frailty in patients undergoing gastrointestinal cancer resection in Japan: a retrospective cohort study

    by Asuka Yasueda, Junichi Nishimura, Seiji Ikeda, Naotsugu Haraguchi, Hirofumi Akita, Hiroshi Wada, Chu Matsuda, Takeshi Omori, Masayoshi Yasui, Hironari Tamiya, et al.

    Purpose: Frailty is a state of physical and cognitive decline that exists between robust health and the need for nursing care. Frailty is reported to occur at a high rate among patients with cancer and is associated with postoperative complications, such as delirium, infection, reduced survival, and rehospitalization. In this study, we investigated the incidence of frailty and surgical outcomes in patients who underwent surgery for gastrointestinal cancer.Methods: A total of 201 patients who underwent preoperative physical assessment at Osaka International Cancer Institute between July and September 2021 were included. The Japanese version of the Cardiovascular Health Study (J-CHS) index was used to assess the frequency of frailty and related postoperative outcomes.Results: Among the 201 patients, 27 (13%) were classified as frail and 126 (63%) as pre-frail. Of the 27 frail patients, 22 (81%) were older adults—a significantly higher proportion compared to the pre-frail/robust group (P=0.004). The median hospital stay for frail patients was 17 days (range, 5–98 days), which was significantly longer than that for robust patients (P<0.001). Postoperative complications occurred in 13 frail patients (48%), which was higher than in pre-frail (n=36, 29%) and robust (n=6, 13%) patients. Furthermore, multivariate analysis showed that frailty was an independent risk factor for postoperative complications.Conclusion: These findings indicate that frailty is common among older adults with gastrointestinal cancer and has a significant impact on both the length of hospital stay and the risk of postoperative complications.

  • Open Access

    Study protocol: A randomized controlled trial of chemoradiotherapy versus chemotherapy as neoadjuvant therapy for resectable pancreatic cancer (CSGO-HBP-027)

    by Yoshito Tomimaru, Hirofumi Akita, Keisuke Tamari, Sakae Maeda, Hiroshi Wada, Yoshifumi Iwagami, Chikato Koga, Naoki Hama, Akira Tomokuni, Shogo Kobayashi, et al.

    Despite advances in multimodal treatment, the long-term survival of patients with resectable pancreatic ductal adenocarcinoma (PDAC) remains poor. In Japan, neoadjuvant chemotherapy with gemcitabine and S-1 (GS) has demonstrated a survival benefit compared with upfront surgery. The addition of radiotherapy to chemotherapy may further improve outcomes by enhancing local tumor control and increasing R0 resection rates; however, no randomized trial has directly compared GS alone with GS plus radiotherapy (GS-RT) in patients with resectable PDAC. The CSGO-HBP-027 trial is a multicenter, randomized phase II/III study designed to evaluate whether neoadjuvant GS-RT improves survival compared with GS alone. This trial will enroll 200 patients with resectable PDAC, who will be randomized in a 1:1 ratio to receive either two cycles of GS or two cycles of GS with concurrent radiotherapy (50.4 Gy in 28 fractions), followed by surgery scheduled 3–8 weeks after completion of neoadjuvant therapy. The primary endpoint is overall survival, and secondary endpoints include resection rate, R0 resection rate, histological tumor response, progression-free survival, and safety. Overall survival will be compared between the two treatment arms using the stratified log-rank test, with adjusted hazard ratios estimated using the Cox proportional hazards model. This trial was registered with the Japan Registry of Clinical Trials (jRCTs051250150). The CSGO-HBP-027 trial will provide evidence on whether neoadjuvant GS-RT improves survival in patients with resectable PDAC compared with GS alone. The results of this study are expected to clarify the optimal neoadjuvant treatment strategy for resectable PDAC and to provide high-quality evidence regarding the clinical value of adding radiotherapy to GS-based neoadjuvant therapy.